Mary Corey
Affiliations: | Health Policy, Management and Evaluation | University of Toronto, Toronto, ON, Canada |
Area:
Health Care Management, Medicine and Surgery, EpidemiologyGoogle:
"Mary Corey"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| McCague AF, Raraigh KS, Pellicore MJ, et al. (2019) Correlating CFTR Function with Clinical Features to Inform Precision Treatment of Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine |
| Kim SO, Corey M, Stephenson AL, et al. (2018) Reference percentiles of FEV1 for the Canadian cystic fibrosis population: comparisons across time and countries. Thorax |
| Stern M, Bertrand DP, Bignamini E, et al. (2016) Standardy opieki Europejskiego Towarzystwa Mukowiscydozy: zarządzanie jakością w zakresie mukowiscydozy ☆ Pediatria Polska. 91 |
| Yau YC, Ratjen F, Tullis E, et al. (2015) Randomized controlled trial of biofilm antimicrobial susceptibility testing in cystic fibrosis patients. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 14: 262-6 |
| Stern M, Bertrand DP, Bignamini E, et al. (2014) European Cystic Fibrosis Society Standards of Care: Quality Management in cystic fibrosis. Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society. 13: S43-59 |
| Ooi CY, Dupuis A, Gonska T, et al. (2014) Does integration of various ion channel measurements improve diagnostic performance in cystic fibrosis? Annals of the American Thoracic Society. 11: 562-70 |
| Schneiderman JE, Wilkes DL, Atenafu EG, et al. (2014) Longitudinal relationship between physical activity and lung health in patients with cystic fibrosis. The European Respiratory Journal. 43: 817-23 |
| Ooi CY, Dupuis A, Ellis L, et al. (2014) Does extensive genotyping and nasal potential difference testing clarify the diagnosis of cystic fibrosis among patients with single-organ manifestations of cystic fibrosis? Thorax. 69: 254-60 |
| Sosnay P, Raraigh K, Vangoor F, et al. (2014) WS13.1 Patients with mutations that permit 3% or more of wild-type CFTR function are associated with higher FEV1 Journal of Cystic Fibrosis. 13: S27 |
| Sosnay PR, Siklosi KR, Van Goor F, et al. (2013) Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nature Genetics. 45: 1160-7 |